Who
Barbara K. Finck
Director
Company insider
Files Form 4 as: Director, Forte Biosciences; Director, Comera Life Sciences Holdings; Chief Medical Officer, Coherus Oncology.
In numbers
- Trades disclosed
- 50
- Buys
- 1
- Sells
- 5
- Bought
- $8,310
- Sold
- $119K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 12 Nov 2014
- Last trade
- 27 Aug 2026
- Last filed
- 27 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —166 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —166 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,353 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,353 | filing |
| 19 Mar 2025filed 21 Mar 2025 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 19 Sep 2023filed 20 Sep 2023 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 4 Jan 2023filed 14 Feb 2023 | Comera Life Sciences Holdingsoption or derivative | SEC FORM 4 Code P | $1,6896,756 at $0.25 | filing |
| 4 Jan 2023filed 14 Feb 2023 | Comera Life Sciences Holdings | SEC FORM 4 Bought | $8,3106,756 at $1.23 | filing |
News
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026CHRS · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Barbara K. Finck; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.